The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: Relation to low-density lipoprotein receptor gene polymorphism

Cardiology

Volumn 111, Issue 2, 2008, Pages 140-146

  Bolewski, Andrzej ^a   Lipiecki, Janusz ^c   Plewa, Robert ^b   Burchardt, Pawel ^a   Siminiak, Tomasz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Adhesion molecules; Atorvastatin; Hypercholesterolemia; Inflammation; Low density lipoprotein receptor

Indexed keywords

ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; ATTENUATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; E-SELECTIN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROBABILITY; PROSPECTIVE STUDIES; PYRROLES; RECEPTORS, LDL; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 50849127808     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119702     Document Type: Article

References (39)

1. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Alderman E, Corley S, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG: Five-years angiografic followup of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993;22:1141-1154.
3. Cushing S, Berliner J, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-5138.
4. Rajavashisth T, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-257.
5. Hackman A, Abe Y, Insull W, et al: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
6. Stefan B, Sandrine B, Laurence T: Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
7. de Beer F, Hind C, Fox K: Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-243.
8. Ridker PM: Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-937.
9. Pasceri V, Willerson J, Yeh E: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
10. Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, Gotto A, Ballantyne C: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
11. Blankenberg S, Rupprecht H, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-1342.
12. Ridker PM, Buring JE, Riifai N: Soluble P-selectin and risk of future cardiovascular events. Circulation 2001;103:491-495.
13. Hwang S, Ballantyne C, Sharrett AR, Smith LC, Davis CE; Gotto AM, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases, the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:4219-4225.
14. Gurfinkel E; Lernoud V: The role of infection and immunity in atherosclerosis. Expert Rev Cardiovasc Ther 2006;4:131-137.
15. Peltonen L, Mc Kusicka V: Genomic and medicine: dissecting human disease in postgenomic area. Science 2001;291:1224-1229.
16. Cullen P, von Eckardstein A, Assmann G: Diagnosis and management of new cardiovascular risk factors. Eur Heart J 1998;19(suppl O):O13-O19.
17. El Messal M, Beaudeux JL, Drissi A, Giral P, Chater R, Bruckert E, Adlouni A, Chapman MJ: Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 2005;366:185-189.
18. Bláha M, Krejsek J, Bláha V, Andrýs C, VokurkováD, Malý J, Blažek M, Skořepová M: Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res 2004;53:273-278.
19. Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, Sassi G, Taddei M, Bionda A: Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997;96:1381-1385.
20. Karasek D, Vaverkova H, Hutyra M, Halenka M, Novotnyy D, Budikova M, Slavik L: Endothelial dysfunction in a family with familial combined hyperlipidemia. Vnitr Lek 2003;49:623-629.
21. Paiker JE, Raal FJ, Veller M, von Arb M, Chetty N, Naran NH: Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chim Acta 2000;293:105-113.
22. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effect of atorvastatin on early recurrent ischemic events in acute coronary syndrome. The MIRACL study. JAMA 2001;285:1711-1718.
23. Bickel C, Rupprecht HJ, Blankenberg S, et al: Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-908.
24. Nawawi H, Osman NS, Annuar R, Khalid B, Yusoff K: Soluble intercellular adhesion molecule-1 and IL-6 reflect endothelial dysfunction in patients with primary hypercholesterolemia treated with atorvastatin. Atherosclerosis 2003;169:283-291.
25. Sampietro T, Bigazzi F, Rossi G, Dal Pino B, Puntoni MR, Sbrana F, Chella E, Bionda A: Upregulation of immune system in primary hypercholesterolemia, effect of atorvastatin therapy. J Intern Med 2005;257:523-530.
26. Alonso R, Mata P, De Andres R, Villacastin BP, Martinez-Gonzalez J, Badimon L: Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001;157:423-429.
27. van Haelst PL, van Doormaal JJ, Asselbergs FW, van Roon AM, Veeger NJ, Henneman MM, Smit AJ, Tervaert JW, May JF, Gans RO: Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin Sci (Lond) 2003;104:627-632.
28. Brown S, Raal F, Panz V, Stevens B, Veller M: High dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolemic patients. Cardiovasc J S Afr 2004;15:70-75.
29. Bo M, Nicolello MT, Fiandra U, Mercadante G, Piliego T, Fabris F: Treatment of heterozygous familial hypercholesterolemia: atorvastatin versus simvastatin. Atherosclerosis 2001;2(suppl):97-98.
30. Ueda M: Familial hypercholesterolemia. Mol Genet Metab 2005;86:423-426.
31. Albert MA, Danielson E, Rifai N, et al: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
32. Nissen SE, Murat Tuzcu E, Schoenhagen P, Brown G, Ganz P, Vogel R, Crowe T, REVERSAL investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:1071-1080.
33. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of soluble markers of endothelial dysfunction after 1 year treatment with atorvastatin and simvastatin in patients with coronary heat disease. Atherosclerosis 2002;162:179-185.
34. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002;251:338-347.
35. Nawawi H, Osman NS, Annuar R, Khalid B, Yusoff K: Reduction in serum levels of adhesion molecules, interleukina-6 and C-reactive protein following short-therm low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Hormon Metab Res 2003;35:479-485.
36. Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF: Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol 2004;94:364-366.
37. Atalar E, Ozmen F, Haznedaroglu I, Acil T, Ozer N, Ovunc K, Aksoyek S, Kes S: Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int J Cardiol 2002;84:227-231.
38. Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT, Ledet T: Diverse effects of inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001;360:363-370.
39. Jilma B, Joukhadar C, Derhasching U, Rassoul F, Richter V, Wolzt M, Dorner GT, Petternel V, Wagner OF: Level of adhesion molecules do not decrease after 3 month of statin therapy in moderate hypercholesterolaemia. Clin Sci (Lond) 2003;104:189-193.